Comparative analysis of refractive predictability and safety of two models of phakic posterior chamber intraocular lenses for the correction of myopia and myopic astigmatism

Session Details

Session Title: Phakic IOLs

Session Date/Time: Sunday 23/09/2018 | 08:00-10:00

Paper Time: 08:34

Venue: Room A3, Podium 1

First Author: : G.Sachdev INDIA

Co Author(s): :                        

Abstract Details

Purpose:

To evaluate the long term refractive outcomes and safety profile of an indigenously manufactured phakic intraocular lens (EYEPCL, Care group, India) and to compare the outcomes with preexisting models (ICL, Visian Staar Surgical).

Setting:

The Eye Foundation, Coimbatore – A tertiary eye care hospital in South India.

Methods:

This interventional comparative case series included the implantation of both spherical or toric phakic intraocular lenses. Eyes with high myopia and myopic astigmatism or those contraindicated for keratoablative procedures were included. Uncorrected and best corrected distance visual acuity (UDVA and CDVA) were noted at preoperative, 1 month, 6 months and 1-year follow-up visit. Dilated slit lamp evaluation for lens position, lens vault using ASOCT (Cirrus HD, Carl Zeiss HD) and specular microscopy was done at each visit (SP-1P, Topcon). Intraoperative and postoperative complications were noted. The minimum follow-up period was one-year.

Results:

In our study 178 eyes and 299 eyes underwent EYEPCL (Group A) and ICL (Group B) implantation. The mean preoperative sphere and cylinder in Group A and B was -9.86D/-2.41D and -9.31D/-2.04D respectively (P > 0.05). Preoperative mean BDVA (LogMAR) was 0.269 and 0.114 in Group A and B. At one-year follow-up mean UDVA was 0.11 and 0.088 respectively. Complications included lens rotation (9 versus 4 eyes), transient IOP rise (3 versus 2 eyes) and cataract (2 eyes each). No significant differences in mean lens vault and endothelial cell loss were noted at one-year follow-up visit

Conclusions:

Refractive outcomes following EYEPCL were similar to previous commercially available ICL at one-year follow-up visit. Intraoperative and postoperative complication rate noted in both cohorts was not significantly different. The EYEPCL offers similar outcomes in safety and efficacy profile as compared to the earlier option, and is a viable method for refractive correction in cases where cost of treatment is a limiting factor.

Financial Disclosure:

-